NCT05526248 2026-03-11
ARAMON
Bayer
Phase 2 Completed
Clinical Trials
15 trialsNCT05999968 2026-03-05
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Eli Lilly and Company
Phase 1 Completed
NCT04736199 2026-02-27
ARANOTE
Bayer
Phase 3 Completed
NCT05202301 2025-08-11
A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely
Bayer
Completed
NCT03568656 2025-08-08
Study to Evaluate CCS1477 in Advanced Tumours
CellCentric Ltd.
Phase 1/2 Completed
NCT05171387 2025-06-22
Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer
Bayer
Phase 2 Completed
NCT06013475 2025-06-12
DEAR-EXT
Bayer
Completed
NCT06498921 2024-10-24
BELBEQA
Bayer
Completed
NCT05362149 2024-03-20
DEAR
Bayer
Completed
NCT02200614 2022-06-28
ARAMIS
Bayer
Phase 3 Completed
NCT01784757 2021-03-17
ARAFOR
Orion Corporation, Orion Pharma
Phase 1 Completed
NCT03237416 2018-11-06
Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers
Bayer
Phase 1 Completed
NCT01317641 2017-03-29
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Orion Corporation, Orion Pharma
Phase 1/2 Completed
NCT01429064 2017-02-20
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Orion Corporation, Orion Pharma
Phase 2 Completed
NCT02671097 2016-09-08
Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate
Bayer
Phase 1 Completed